New York, NY -- (SBWIRE) -- 01/23/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: RadNet Inc (NASDAQ:RDNT), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Calix Inc (NYSE:CALX), Cardica, Inc (NASDAQ:CRDC)
RadNet Inc (NASDAQ:RDNT) showed a volume of 1.18 million shares by the end of last trade whereas the average volume of the stock remained 215,369.00 shares. The stock opened the session at $1.62 but then moved to $1.66. At that price, the stock showed a positive performance of 1.22%. RadNet, Inc. (RadNet) is engaged in providing freestanding, fixed-site outpatient diagnostic imaging services in the United States. The Company's services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET),
Will RDNT Continue To Move Higher? Find Out Here
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) opened the session at $6.07 and closed the session at $6.17. The stock showed a positive performance of 1.65% in previous trading session. Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
For How Long MACK will fight for Profitability? Read This Trend Analysis report
Calix Inc (NYSE:CALX) opened the session at $8.37 and closed the session at $8.54. The stock showed a positive performance of 1.67% in previous trading session.The beta of the stock remained 1.58. Calix, Inc. (Calix) is a provider in North America of broadband communications access systems and software for fiber- and copper-based network architectures that enable communications service providers (CSPs) to connect to their residential and business subscribers.
Why Should Investors Buy CALX After The Recent Gain? Just Go Here and Find Out
Cardica, Inc (NASDAQ:CRDC) the stock decreased -2.56% and finished the session at $1.14. Traded with volume of 1.16 million shares in the prior session and the average volume of the stock remained 437,150.00 shares. The beta of the stock remained 1.14. Cardica, Inc. (Cardica) is focused on the development of an endoscopic microcutter product line intended for use by thoracic, bariatric, colorectal and general surgeons.
Will CRDC Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)